TREATMENT OF BACTERIAL VAGINOSIS WITH ORAL OR VAGINAL ORNIDAZOLE, SECNIDAZOLE AND METRONIDAZOLE

Objective: To evaluate the clinical efficacy and tolerance of oral or vaginal ornidazole, secnidazole and metronidazole or their combination s for treatment of bacterial vaginosis. Method: In an open, randomized , prospective study, 152 patients with bacterial vaginosis according t o Amsel's criteria were included into the study. The patients were div ided into eight groups: (1) oral ornidazole 2 x 500 mg/day for 5 days; (2) vaginal ornidazole 500 mg/day for 5 days; (3) oral and vaginal or nidazole for 5 days; (4) oral secnidazole 2 g in a single dose; (5) or al secnidazole 2 g in a single dose and vaginal ornidazole 500 mg/day for 5 days; (6) oral secnidazole 2 g in a single dose and vaginal metr onidazole 2 x 500 mg/day for 7 days; (7) oral ornidazole 2 x 500 mg/da y for 5 days and vaginal metronidazole 2 x 500 mg/day for 7 days; and (8) vaginal metronidazole 2 x 500 mg/day for 7 days. None of the partn ers received any treatment. Result: We found a 100% cure rate in both oral and vaginal ornidazole and oral secnidazole-vaginal metronidazole groups. Conclusion: Vaginal treatments including ornidazole and metro nidazole are not as effective as both oral and vaginal drug combinatio ns. (C) 1998 International Federation of Gynecology and Obstetrics.